On February 18, 2010
FDA Ruling Is a Relief for Amgen’s Anemia Drugs, but the Storm’s Not Over Yet
The FDA’s new safety plan for Amgen (AMGN)’s $5 billion anemia franchise could have been worse, but regulatory, reimbursement and competitive challenges are just around the corner.
No tags for this post.
0 Comments